A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 9, 2018

Primary Completion Date

September 29, 2019

Study Completion Date

September 29, 2019

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Specified dose on specified days

DRUG

Ipilimumab

Specified dose on specified days

Trial Locations (17)

27

Local Institution, Lima

8500

Local Institution, Viedma

17604

Local Institution, Lancaster

18840

Local Institution, Sayre

19047

Local Institution, Langhorne

22927

Local Institution, Großhansdorf

29414

Local Institution, Charleston

43210

Local Institution, Columbus

68506

Local Institution, Lincoln

70839

Local Institution, Gerlingen

82131

Local Institution, Gauting

84770

Local Institution, St. George

94115

Local Institution, San Francisco

07601

Local Institution, Hackensack

H1M 1B1

Local Institution, Montreal

01307

Local Institution, Dresden

Unknown

Local Institution, Lima

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY